-
Kenya's economy faces climate change risks: World Bank
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Trump signs $900 bn defense policy bill into law
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
British energy giant BP extends shakeup with new CEO pick
-
EU kicks off crunch summit on Russian asset plan for Ukraine
-
Sri Lanka plans $1.6 bn in cyclone recovery spending in 2026
-
Most Asian markets track Wall St lower as AI fears mount
-
Danish 'ghetto' tenants hope for EU discrimination win
-
What to know about the EU-Mercosur deal
-
Trump vows economic boom, blames Biden in address to nation
-
ECB set to hold rates but debate swirls over future
-
EU holds crunch summit on Russian asset plan for Ukraine
-
Nasdaq tumbles on renewed angst over AI building boom
-
Billionaire Trump nominee confirmed to lead NASA amid Moon race
-
CNN's future unclear as Trump applies pressure
-
German MPs approve 50 bn euros in military purchases
-
EU's Mercosur trade deal hits French, Italian roadblock
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Warner Bros. Discovery rejects Paramount bid
-
Doctors in England go on strike for 14th time
-
Ghana's Highlife finds its rhythm on UNESCO world stage
-
Stocks gain as traders bet on interest rate moves
-
France probes 'foreign interference' after malware found on ferry
-
Europe's Ariane 6 rocket puts EU navigation satellites in orbit
-
Bleak end to the year as German business morale drops
-
Hundreds queue at Louvre museum as strike vote delays opening
-
Markets rise even as US jobs data fail to boost rate cut bets
-
Asian markets mixed as US jobs data fails to boost rate cut hopes
-
Bondi shooting shocks, angers Australia Jewish community
-
UK experiences sunniest year on record
Nobel chemistry winner sees engineered proteins solving tough problems
Whether it's battling tumors or breaking down plastic, American scientist David Baker, co-recipient of this year's Nobel Prize in Chemistry, has an answer: engineering proteins that don't naturally exist -- a concept once dismissed as "crazy."
Today, proteins with novel functions are flowing steadily out of his lab, with an endless list of potential applications ranging from ultra-targeted therapies to the development of new vaccines.
"Across the range of problems that we face today in medicine and health, sustainability, energy, and technology, I think the potential for protein design is enormous," Baker told AFP via video call from Seattle, hours after learning of his Nobel win alongside two other laureates.
Proteins are organic molecules that play a fundamental role in almost every function of living organisms, from muscle contraction and food digestion to neuron activation and more.
"The ones in nature evolved to solve all the problems that were faced during natural selection," explained the 62-year-old University of Washington professor.
"But humans face new problems today," added the biochemist and computational biologist.
"We're heating up the planet, so we need new solutions in ecology and sustainability. We live longer, so there's new diseases which are relevant, like Alzheimer's disease. There's new pathogens like coronavirus."
Rather than leave these problems up to evolution -- a "brutal" solution that would take a very, very long time -- "with new proteins, we can solve those problems, but in a very short time," he said.
- From fringe to mainstream -
All proteins are composed of chains of amino acids, whose sequence dictates their shape -- and ultimately their function.
For decades, scientists have tried to determine protein structures based on these amino acid sequences.
In the late 1990s, Baker made strides towards solving this problem with a computer software he developed called Rosetta.
His success prompted a shift his focus to the reverse approach: starting with a desired shape and using Rosetta to identify the corresponding amino acid sequence. This sequence can then be introduced into bacteria, which synthesize the new protein that can be harvested and studied.
In 2003, he published his breakthrough finding -- the creation of the first-ever protein not found in nature -- though it still lacked a defined function.
"Then we started trying to design proteins that actually would do useful things," Baker recalled. "And that's when people, I think, really started thinking it was crazy."
But "for the last 20 years -— and really, most recently, the last five years -— we've been able to make proteins that do all kinds of amazing things," he said. Rosetta meanwhile has been progressively improved to incorporate artificial intelligence.
"I think what's kind of funny now is that the lunatic fringe, which pretty much no one was doing, has now entered the mainstream," he added with a laugh.
- Keys that fit locks -
How do scientists decide what shape a new protein needs to achieve the desired function?
Baker gives the example of a tumor. "We know some protein that's on the surface of that tumor, and we know its shape. What we do is we design a protein that acts like a key fitting into a lock," he explained.
Another application: breaking down plastic. In this case, a protein is designed to attach itself to the plastic molecule, accompanied by chemical compounds to "cut" it.
In medicine, this technology has already been used in a Covid-19 vaccine approved in South Korea. Researchers are also exploring its potential to create new materials.
"In biology, we have tooth and bone, we have shells, which are made by proteins interacting with inorganic compounds like calcium carbonate or calcium phosphate," says Baker, envisioning proteins interacting with other compounds to create entirely new materials with unique properties.
Greenhouse gas capture, a universal flu vaccine, improved antivenom -- Baker's wish list goes on and on.
"As protein design becomes more powerful, I'm incredibly excited about all the problems that we will be able to solve."
P.Petrenko--CPN